Marksans Pharma announces USFDA approval for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg

Marksans Pharma Ltd has announced that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg of Abbvie Inc.

Shares of MARKSANS PHARMA LTD. was last trading in BSE at Rs.54.6 as compared to the previous close of Rs. 53.25. The total number of shares traded during the day was 1469865 in over 5930 trades.

The stock hit an intraday high of Rs. 56 and intraday low of 53.1. The net turnover during the day was Rs. 80462643.

Source : Equity Bulls

Keywords